Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transarterial idarubicin versus epirubicin chemoembolization for primary liver cancer
ChiCTR2100041984Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in hepatocellular carcinoma (HCC) comparing Idarubicin + TACE with Epirubicin + TACE (2 arms). Primary endpoint: Objective response rate (ORR). Started Feb 2021; status: recruiting.
02
Drugs
idarubicinepirubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100041984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041984.